In clinical trials
Heart & blood
Balixafortide
Evidence
Clinical trials
Class
CXCR4 antagonist peptide
KEY TAKEAWAY
Balixafortide is a synthetic cyclic peptide that blocks the CXCR4 receptor. It has been studied for metastatic breast cancer alongside chemotherapy. Balixafortide is not FDA-approved. A phase 3 trial combined with eribulin did not meet its main goal.
Written by the Veylo editorial team · Updated
November 2026
What it is
CXCR4 antagonist peptide
Being studied for
Studied in metastatic breast cancer
Key fact
Balixafortide is not FDA-approved. A phase 3 trial combined with eribulin did not meet its main goal.
Route
Intravenous infusion in trials
Evidence strength
Clinical trials
Balixafortide is a synthetic cyclic peptide that blocks the CXCR4 receptor. It has been studied for metastatic breast cancer alongside chemotherapy.
Blocking CXCR4 may make tumors more vulnerable to chemotherapy and to immune attack.
Balixafortide is not FDA-approved. A phase 3 trial combined with eribulin did not meet its main goal.
Studied in metastatic breast cancer.
Infusion reactions and injection-related effects were reported in trials.
Balixafortide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.